Cellid Co., Ltd. (299660)
KRX SM KRX SM Primary Summary
Cellid Co., Ltd. (299660) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Cellid Co., Ltd. ever had a stock split?
Cellid Co., Ltd. Profile
| Biotechnology Industry | Healthcare Sector | Yuil Kang Chang CEO | KRX SM Exchange | KR7299660001 ISIN |
| KR Country | - Employees | - Last Dividend | 18 Jul 2023 Last Split | - IPO Date |
Overview
Cellid, Co., Ltd., established in 2006 and located in Seoul, South Korea, is at the forefront of developing cutting-edge immunotherapeutic vaccines aimed at tackling cancer and infectious diseases. The company's cutting-edge approach involves developing specific vaccines that target various cancers by harnessing the body's immune response to fight these diseases. Through its innovative research, Cellid is contributing significantly to the global effort in combating cancer and infectious diseases, showcasing a commitment to improving patient outcomes and advancing healthcare.
Products and Services
- BVAC-C
Designed for patients with cervical, head and neck, anal, and sex organ cancer related to human papilloma virus (HPV) infection. BVAC-C aims to leverage the body’s immune response against cancer cells infected by HPV, offering a targeted immunotherapy solution.
- BVAC-B
Targets stomach, breast, and ovarian cancer expressing the HER-2/neu antigen. BVAC-B is designed to stimulate the immune system to recognize and attack cancer cells with this specific antigen, providing a promising therapeutic option for HER-2/neu positive cancer patients.
- BVAC-P
Focused on combating prostate cancer, renal cell cancer, and glioblastoma by targeting prostate acid phosphatase (PAP) and prostate-specific membrane (PSMA) antigens. BVAC-P is an advanced immunotherapy that aims at cancers expressing these specific antigens, offering hope to patients with these challenging diagnoses.
- BVAC-M
Developed for melanoma and other cancers expressing the GP100/MAGE-A3 antigens. By targeting these specific antigens, BVAC-M helps to harness the immune system’s power to fight melanoma and other related cancers, promoting better clinical outcomes.
- BVAC-Neo
A customized immunotherapeutic vaccine tailored to the individual patient’s cancer. By analyzing the unique characteristics of the patient's tumor, BVAC-Neo provides a personalized therapy, aiming to improve treatment efficacy and patient survival rates.
- COVID-19 Prevention Vaccines
Responding to the global pandemic, Cellid is also engaged in developing vaccines aimed at preventing COVID-19. These vaccines are part of Cellid’s efforts to address infectious diseases and public health crises, alongside its cancer-focused therapies.
